For three years, tirzepatide held the crown for the most weight a drug could melt off a human body in a clinical trial. Then a triple-hormone molecule from Eli Lilly walked into a Phase 3 study and pulled off something the obesity field had quietly assumed was impossible without a scalpel: an average of roughly 28% of body weight gone, with nearly half of patients on the top dose losing 30% or more. That molecule is retatrutide, and the numbers are the reason every endocrinologist I know has it bookmarked.
Quick answer: Retatrutide is an investigational once-weekly injection from Eli Lilly that activates three gut and metabolic hormone receptors at once (GLP-1, GIP, and glucagon). In trials it produced larger average weight loss than any approved obesity drug to date, up to about 24% in Phase 2 and roughly 28% in Phase 3. It is not yet FDA approved.
What is retatrutide?
Retatrutide (research code LY3437943) is a single engineered peptide that does the work of three. Most of the blockbuster weight-loss drugs you have heard of hit one or two targets. Semaglutide (Wegovy, Ozempic) is a pure GLP-1 agonist. Tirzepatide (Zepbound, Mounjaro) is a dual agonist, hitting GLP-1 and GIP. Retatrutide adds a third lever: the glucagon receptor.
That third receptor is the interesting part, and it is a bit counterintuitive. Glucagon usually raises blood sugar, so adding it to a diabetes-adjacent drug sounds backwards. The bet Lilly made is that glucagon agonism increases energy expenditure, basically nudging the body to burn more fuel, while the GLP-1 and GIP components handle appetite suppression and insulin response. Pull all three at once and you get appetite down and metabolic rate up at the same time (per Lilly’s description of the molecule’s mechanism, lilly.com).
Why does hitting three receptors matter?
The reason a triple agonist can outrun a single or dual one comes down to a simple idea: body weight is a balance between energy in and energy out, and each receptor pulls a different side of that scale.
GLP-1 and GIP work mostly on the “energy in” side. GLP-1 slows stomach emptying and signals fullness to the brain, so meals satisfy you sooner and portions shrink without a constant fight against hunger. GIP on its own is a weak weight signal, but layered on top of GLP-1 it seems to sharpen the appetite effect and soften some of the nausea, which is part of why these combination drugs are tolerated at doses that actually move the scale.
Glucagon is the piece retatrutide adds, and it works on the “energy out” side. Glucagon-receptor activation is thought to raise energy expenditure and pull fat out of the liver. So while the appetite arms are lowering how much you eat, the glucagon arm is nudging your body to burn more. Attacking both sides at once is the mechanistic reason retatrutide reached a weight-loss tier no approved drug has matched in trials.
Here is the counterintuitive tension a lot of coverage skips. Glucagon normally raises blood sugar, which sounds like the opposite of what a metabolic drug should do. The bet Lilly made is that the GLP-1 component keeps glucose in check while glucagon does its fat-burning work. Get that three-way ratio wrong and you would trade fat loss for worse blood sugar, which is exactly why building a balanced triple agonist took years longer than a dual one.
The simplest way to actually get this done
Superpower is a full-body lab membership that runs 100+ biomarkers, has each result reviewed by a doctor, and tracks your numbers year over year (about $199/year). It is what we point readers to when they would rather get one clean, complete draw than chase single tests one at a time. Here is superpower reviewed in full.
How much weight did people lose on retatrutide?
This is where retatrutide stopped being just another pipeline drug and started making headlines.
The Phase 2 trial, led by Ania Jastreboff and published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity or overweight and no type 2 diabetes. After 48 weeks on the highest dose (12 mg weekly), the average weight loss was about 24.2%, compared with roughly 2.1% for placebo (nejm.org). At the 24-week mark the top dose was already around 17.5% (Eli Lilly). For context, a quarter of body weight is the territory people used to reach only with bariatric surgery.
Then the Phase 3 data landed and somehow raised the bar again. On May 21, 2026, Lilly reported topline results from TRIUMPH-1, a 2,339-patient trial in adults with obesity (or overweight plus a weight-related condition) and no type 2 diabetes. At 80 weeks, mean weight loss reached about 28.3% on the 12 mg dose versus roughly 2.2% on placebo, and 45.3% of those on the top dose lost 30% or more of their starting weight (AJMC). Looked at through the efficacy estimand (patients who stayed on treatment as intended), the figure climbed to about 30.3%.
Put a person to those percentages and it gets vivid. A 230-pound adult losing 28% is down roughly 64 pounds. That is not a slimmer waistline, that is a different body.
What do those numbers actually mean day to day?
A percentage on a slide is easy to gloss over, so it is worth translating the trial data into what a person would actually experience, and where the fine print sits.
The results are averages, and individual results vary a lot. A mean of 28% means some people lost far more and some far less. Genetics, starting weight, dose tolerated, diet, and activity all shift where an individual lands. The headline number is a center of gravity, not a promise.
The missing plateau is the eye-catching part. In the Phase 2 trial, the weight-loss curve had not flattened at 48 weeks, meaning people were still losing when the study stopped. That is unusual. Most diets and drugs hit a plateau as the body defends its new set point. A drug that had not yet found its ceiling is why the obesity field paid attention, though it also means the true long-term average is something later data has to pin down.
Not all of the loss is fat. As with any rapid weight loss, a share of what comes off is lean muscle, not just fat. That is the tissue you least want to lose, and the countermeasures are the same ones that apply to any weight-loss method: keep protein high and do resistance training throughout. Skip those and you can hit a goal weight while ending up weaker and metabolically worse off than the scale implies.
It behaves like a long-term therapy, not a course you finish. The appetite changes these drugs create are borrowed, not permanent. Withdrawal studies across this class show that when people stop, hunger returns and a large share of the lost weight comes back within roughly a year. That reframes retatrutide from a quick fix into an ongoing treatment decision, with all the cost and commitment that implies. It is one more reason the online “buy a few vials” pitch misreads what this drug is.
Put those caveats together with a realistic scenario. Imagine a 210-pound adult who reaches the top dose after several months of careful titration and lands near the trial average. The scale drops steadily, clothes fit differently, blood pressure and triglycerides improve, and the early nausea has long since faded. That same person also keeps up resistance training and protein to protect muscle, and understands that stopping the drug likely means the appetite, and some of the weight, returns. That is the honest full picture: powerful, but a commitment rather than a cure.
Is retatrutide approved yet?
No. As of June 2026, retatrutide is investigational and not approved by the FDA or any other regulator. The only legal way to receive it is by enrolling in one of Lilly’s clinical trials (lilly.com).
Here is the part worth saying plainly, because it matters for safety. Retatrutide’s name is all over the internet right now, sold in vials by “research peptide” sites that ship it as a so-called not-for-human-use chemical. That product is unapproved, unregulated, and not quality-controlled for human injection. You have no guarantee of dose, purity, or sterility. The trial results below come from pharmaceutical-grade material under medical supervision, which is a very different thing from a vial bought online.
The TRIUMPH Phase 3 program is broad: beyond obesity, Lilly is studying retatrutide in type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, cardiovascular and kidney outcomes, and metabolic liver disease (lilly.com). A regulatory filing is expected to follow the completion of these pivotal studies, which realistically puts any approval into the 2027-2028 window. Treat single-date predictions you see online with skepticism, because the FDA timeline is not public.
It is worth being blunt about why the grey market is dangerous rather than just illegal. With an unregulated vial you have no assurance of the actual dose, no proof of purity or sterility, and no clinician watching for the side effects that need managing. Regulators inspecting seized “research peptide” products have documented incorrect peptide sequences, heavy metals, and bacterial contaminants. Because retatrutide never had an approved version, it also never qualified for the compounding exemptions that briefly covered semaglutide and tirzepatide during shortages, so the legal cover some sellers imply simply does not exist. The FDA has issued waves of warning letters to peptide sellers, making clear that a “not for human use” label does not make injecting the product safe.
The breadth of the TRIUMPH program is also a clue to how seriously Lilly is taking this molecule. Beyond obesity, retatrutide is being studied in type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, cardiovascular and kidney outcomes, and metabolic liver disease. Those are not marketing add-ons. They are the large, long trials regulators expect before approving a drug that millions might take for years, and they are the reason a realistic timeline stretches into the 2027 to 2028 window rather than next quarter.
How does retatrutide compare to tirzepatide and semaglutide?
The honest comparison comes with a caveat editors like me have to flag: these numbers come from separate trials with different patients and durations, so head-to-head conclusions are inference, not proof. Lilly has not run retatrutide directly against tirzepatide. That said, the gap is hard to ignore.
- Semaglutide (Wegovy): in the SURMOUNT-5 head-to-head trial, semaglutide produced about 13.7% average weight loss at 72 weeks (Eli Lilly).
- Tirzepatide (Zepbound): roughly 15% to 21% in SURMOUNT-1 depending on dose, and 20.2% in that same head-to-head SURMOUNT-5 trial.
- Retatrutide: roughly 28% at 80 weeks in TRIUMPH-1, with a sizable share crossing 30%.
The pattern that jumps out is the dose response. In Phase 2, retatrutide showed almost no weight-loss plateau out to 48 weeks, meaning patients were still dropping pounds when the trial ended. That is the signature of a drug whose ceiling we have not found yet.
What are the side effects of retatrutide?
The side effect profile is, in a word, familiar. Retatrutide behaves like the rest of the incretin class. The most common adverse events in both Phase 2 and Phase 3 were gastrointestinal: nausea, vomiting, diarrhea, constipation, and reduced appetite. Most were mild to moderate and tied to how fast the dose was increased (nejm.org).
The dose tells the story on tolerability. In TRIUMPH-1, treatment discontinuations due to side effects rose with the dose: about 4.1% on 4 mg, 6.9% on 9 mg, and 11.3% on 12 mg (AJMC). In other words, the dose that delivers the jaw-dropping weight loss is also the one a meaningful minority of people could not stay on. That trade-off is exactly what the slow titration schedule is built to manage.
One signal worth watching is heart rate. Because of the glucagon component and its effect on metabolism, earlier studies noted dose-dependent increases in heart rate, which is a parameter regulators will scrutinize closely. On the positive side, TRIUMPH-1 reported favorable shifts in cardiometabolic markers including blood pressure, triglycerides, and non-HDL cholesterol.
Who might retatrutide suit, and how would treatment actually work?
Since the drug is not available outside trials yet, this is a forward-looking picture rather than a prescription, but the shape of it is already clear from how the rest of the class is used.
The people most likely to be candidates are adults with obesity, or with overweight plus a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea, who have not reached their goals with lifestyle changes alone. That is the population the trials enrolled, and it is where the benefit most clearly outweighs the burden of a long-term injectable.
Treatment would almost certainly follow the same disciplined pattern as tirzepatide and semaglutide. A clinician confirms the drug is appropriate, checks baseline labs and history, starts at a low dose, and steps it up gradually over months so the gut can adapt and the nausea stays manageable. Along the way they watch the things that need watching, including heart rate, given the glucagon component, and they adjust the pace if side effects flare. That supervision is not bureaucracy, it is the difference between a drug that works and a hospital visit.
If the scale will not move and you suspect something metabolic is in the way, the sensible step available today is not a grey-market vial. It is a proper workup with a clinician who can prescribe what is actually approved and check whether insulin resistance, thyroid, or hormones are the real obstacle.
Want a real clinician to run the numbers, not a guess?
Joi + Blokes is a telehealth clinic that prescribes GLP-1 medication (Zepbound, compounded semaglutide and tirzepatide), hormone therapy (TRT, HRT), thyroid care, and peptides after a real lab panel and clinician review, with no membership or consult fee (prescriptions from about $59/month, lab panels from $149). If the scale will not budge, this is where you find out whether insulin, thyroid, or hormones are the real reason. Here is Joi + Blokes reviewed in full.
Frequently asked questions
Is retatrutide the same as Mounjaro or Ozempic?
No. Mounjaro/Zepbound is tirzepatide (a dual GLP-1/GIP agonist) and Ozempic/Wegovy is semaglutide (a single GLP-1 agonist). Retatrutide is a triple agonist that also targets the glucagon receptor, and it is not yet approved or sold as a branded product.
Can I buy retatrutide legally right now?
There is no FDA-approved retatrutide product to buy. Vials sold online as research peptides are unapproved and not quality-controlled for human use, which carries real safety risk. The only sanctioned access is through a clinical trial.
How much weight does retatrutide cause people to lose?
In the Phase 3 TRIUMPH-1 trial, average weight loss was about 28.3% at 80 weeks on the 12 mg dose, with 45.3% of those patients losing 30% or more (AJMC). Individual results vary widely.
When will retatrutide be FDA approved?
No approval date is set. Phase 3 trials are still completing as of 2026, and any filing and review would likely push availability into the 2027-2028 range. Be wary of specific dates posted on supplement or peptide sites.
Will the weight come back if I stop retatrutide?
Most likely yes, at least in part. Like other drugs in this class, retatrutide manages appetite signals rather than permanently resetting them, and withdrawal studies across the class show a large share of lost weight returns within about a year of stopping. It is best thought of as an ongoing therapy, which is a conversation to have with a clinician before starting.
Does retatrutide cause muscle loss?
Some of any rapid weight loss is lean mass, and retatrutide is no exception. The protection is the same as for any weight-loss approach: eat enough protein and do regular resistance training while you lose, so more of what comes off is fat rather than muscle.
Why do people talk about a heart rate increase with retatrutide?
Because of the glucagon component and its effect on metabolism, trials noted a dose-dependent rise in heart rate. It is one of the parameters regulators will scrutinize closely as the Phase 3 safety data matures, which is part of why the full dataset matters before drawing firm conclusions about safety.
This article is for general information and is not medical advice. Retatrutide is investigational and not FDA approved. Do not start, stop, or source any weight-loss medication without talking to a licensed clinician who knows your health history.
Reviewed against published trial data from the New England Journal of Medicine, Eli Lilly investor releases, and AJMC reporting on the TRIUMPH-1 Phase 3 results. Last updated June 2026.
Related reading
Related: best GLP-1 telehealth providers for 2026.
